RxDoctor Payments Data

Zane Waji Dean, MD

Cardiovascular Disease · Lima, OHNPI 1336182245

Payments from drug & device makers

$6,850in general payments, 2019–2025

Across 123 payments — averaging $55.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$3K
  • Edwards Lifesciences$1K
  • Abiomed$370
  • Johnson & Johnson$297
  • Amgen$255
  • AstraZeneca$230
  • plus $983 from 17 others

What the payments were for

  • Consulting fees$70%
  • Grants$1232%
  • Travel & lodging$3,72554%
  • Food & beverage$2,81641%
  • Education$1803%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,850 in reported general payments places this provider in the 70th percentile of 827 cardiovascular disease providers in Ohio.

See all cardiovascular disease providers in Ohio

Medicare billing

Part B allowed, 2024
$257,962
Medicare patients
1,051
Services billed
3,072

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban253$320,326
Repatha SureclickEvolocumab56$72,595
Droxidopa16$57,249
EntrestoSacubitril/Valsartan33$47,084
XareltoRivaroxaban28$41,874
FarxigaDapagliflozin Propanediol23$27,590
Praluent PenAlirocumab14$18,725
Prasugrel Hcl106$18,501
Metoprolol Succinate427$5,792
Ranolazine ErRanolazine61$5,525
Atorvastatin Calcium514$4,766
Midodrine Hcl90$4,727
Potassium Chloride240$4,529
ClopidogrelClopidogrel Bisulfate385$4,475
Nebivolol Hcl36$3,125

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$208$320,326253 claims
NovartisEntresto$157$47,08433 claims
Johnson & JohnsonXarelto$297$41,87428 claims
AstraZenecaFarxiga$230$27,59023 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 827 cardiovascular disease providers in Ohio.

Other cardiovascular disease in Lima

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →